Invivyd (IVVD) Competitors $1.63 +0.21 (+14.79%) Closing price 10/7/2025 04:00 PM EasternExtended Trading$1.64 +0.01 (+0.31%) As of 08:32 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IVVD vs. ESPR, ORGO, CMPX, BCYC, PRTA, RGNX, SLDB, CTMX, FULC, and INBXShould you be buying Invivyd stock or one of its competitors? The main competitors of Invivyd include Esperion Therapeutics (ESPR), Organogenesis (ORGO), Compass Therapeutics (CMPX), Bicycle Therapeutics (BCYC), Prothena (PRTA), REGENXBIO (RGNX), Solid Biosciences (SLDB), CytomX Therapeutics (CTMX), Fulcrum Therapeutics (FULC), and Inhibrx Biosciences (INBX). These companies are all part of the "pharmaceutical products" industry. Invivyd vs. Its Competitors Esperion Therapeutics Organogenesis Compass Therapeutics Bicycle Therapeutics Prothena REGENXBIO Solid Biosciences CytomX Therapeutics Fulcrum Therapeutics Inhibrx Biosciences Esperion Therapeutics (NASDAQ:ESPR) and Invivyd (NASDAQ:IVVD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends. Do institutionals & insiders have more ownership in ESPR or IVVD? 47.4% of Esperion Therapeutics shares are held by institutional investors. Comparatively, 70.4% of Invivyd shares are held by institutional investors. 1.7% of Esperion Therapeutics shares are held by insiders. Comparatively, 25.4% of Invivyd shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more volatility & risk, ESPR or IVVD? Esperion Therapeutics has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Comparatively, Invivyd has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500. Does the media prefer ESPR or IVVD? In the previous week, Invivyd had 6 more articles in the media than Esperion Therapeutics. MarketBeat recorded 14 mentions for Invivyd and 8 mentions for Esperion Therapeutics. Invivyd's average media sentiment score of 0.47 beat Esperion Therapeutics' score of 0.30 indicating that Invivyd is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Esperion Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Invivyd 2 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate ESPR or IVVD? Esperion Therapeutics presently has a consensus target price of $7.00, suggesting a potential upside of 126.54%. Invivyd has a consensus target price of $5.14, suggesting a potential upside of 215.18%. Given Invivyd's stronger consensus rating and higher probable upside, analysts clearly believe Invivyd is more favorable than Esperion Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Esperion Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50Invivyd 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.83 Which has higher valuation & earnings, ESPR or IVVD? Esperion Therapeutics has higher revenue and earnings than Invivyd. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEsperion Therapeutics$332.31M1.87-$51.74M-$0.49-6.31Invivyd$25.38M7.72-$169.93M-$0.92-1.77 Is ESPR or IVVD more profitable? Esperion Therapeutics has a net margin of -35.84% compared to Invivyd's net margin of -238.33%. Esperion Therapeutics' return on equity of 0.00% beat Invivyd's return on equity.Company Net Margins Return on Equity Return on Assets Esperion Therapeutics-35.84% N/A -28.41% Invivyd -238.33%-177.89%-90.96% SummaryInvivyd beats Esperion Therapeutics on 9 of the 16 factors compared between the two stocks. Get Invivyd News Delivered to You Automatically Sign up to receive the latest news and ratings for IVVD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IVVD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IVVD vs. The Competition Export to ExcelMetricInvivydMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$170.60M$3.35B$6.12B$10.65BDividend YieldN/A2.29%5.70%4.74%P/E Ratio-1.7721.4185.6626.85Price / Sales7.72466.25622.88135.13Price / CashN/A47.6737.7861.77Price / Book2.9110.0613.216.70Net Income-$169.93M-$52.22M$3.30B$276.44M7 Day Performance33.61%4.25%3.95%2.48%1 Month Performance40.52%12.50%8.40%8.79%1 Year Performance79.81%26.68%88.36%34.41% Invivyd Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IVVDInvivyd3.5782 of 5 stars$1.63+14.8%$5.14+215.2%+76.9%$170.60M$25.38M-1.77100News CoverageAnalyst ForecastGap UpHigh Trading VolumeESPREsperion Therapeutics3.8244 of 5 stars$2.64-0.4%$7.00+165.2%+51.5%$534.30M$332.31M-5.39200ORGOOrganogenesis3.8602 of 5 stars$4.26+3.9%$7.33+72.1%+38.5%$520.12M$482.04M-30.43950CMPXCompass Therapeutics2.6326 of 5 stars$3.82+2.1%$13.88+263.2%+86.1%$517.18MN/A-8.4920News CoveragePositive NewsAnalyst ForecastBCYCBicycle Therapeutics3.4174 of 5 stars$7.61+2.8%$22.22+192.0%-65.8%$512.87M$35.28M-2.17240Trending NewsPRTAProthena3.0751 of 5 stars$9.76+3.7%$19.75+102.4%-38.7%$506.54M$135.16M-1.73130News CoverageAnalyst ForecastGap UpRGNXREGENXBIO4.4979 of 5 stars$9.85+2.1%$28.38+188.1%+10.4%$487.46M$83.33M-2.86370News CoverageAnalyst ForecastSLDBSolid Biosciences2.6796 of 5 stars$5.97-2.9%$15.00+151.3%-16.2%$478.89M$8.09M-2.13100Positive NewsCTMXCytomX Therapeutics4.1085 of 5 stars$3.23+11.4%$5.42+67.7%+184.6%$478.25M$138.10M5.77170FULCFulcrum Therapeutics0.9512 of 5 stars$8.67-1.9%$9.60+10.7%+158.8%$478.17M$80M-7.11100INBXInhibrx Biosciences0.8398 of 5 stars$32.31-1.1%N/A+119.4%$473.38M$200K-3.05166Positive News Related Companies and Tools Related Companies ESPR Competitors ORGO Competitors CMPX Competitors BCYC Competitors PRTA Competitors RGNX Competitors SLDB Competitors CTMX Competitors FULC Competitors INBX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IVVD) was last updated on 10/8/2025 by MarketBeat.com Staff From Our Partners$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredTrump to get REVENGE on the banks??Rumors are swirling that Trump could target the banking system by upending the $5 trillion-a-day SWIFT network...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredU.S. Government Blocked NVIDIA’s Buyout… Here’s WhyThe U.S. government doesn't normally block billion-dollar tech deals. But when NVIDIA tried to acquire this...Behind the Markets | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invivyd, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Invivyd With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
